Amgen Expects Cinacalcet Phase IIIb Trials To Increase Physician Awareness
Executive Summary
Amgen is trying to increase physician awareness of the hyperparathyroidism agent cinacalcet prior to launch by conducting Phase IIIb studies, Exec VP-Global Commercial Operations George Morrow said
You may also be interested in...
Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target
Amgen's chronic kidney disease therapy Sensipar will be available within the next few weeks following FDA's March 8 approval, the company said
Sensipar Hypocalcemia Studies Are Key To Expanded Indication, Amgen Says
Long-term hypocalcemia safety studies will be necessary before Amgen gains approval of an expanded indication for the chronic kidney disease agent Sensipar
Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target
Amgen's chronic kidney disease therapy Sensipar will be available within the next few weeks following FDA's March 8 approval, the company said